Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the interest coverage ratio high or low?
The interest coverage ratio of 0.60x is 116% above its 4-year average of -3.74x, near the high end of its 4-year range (-10.24x–3.39x).
42.67% below its 12-month average of 1.05x.
Reported quarterly interest coverage; no daily interpolation. Q2 FY2026 (2026-06-30): 3.29x.
INTEREST COVERAGE RATIO
0.60x
INTEREST COVERAGE RATIO AVG TTM
1.05x
INTEREST COVERAGE RATIO AVG 3Y
-2.69x
INTEREST COVERAGE RATIO AVG 5Y
-3.74x
INTEREST COVERAGE RATIO AVG 10Y
-10.82x
INTEREST COVERAGE RATIO AVG 15Y
N/A
INTEREST COVERAGE RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-42.67%
CURRENT VS 3Y AVG
+122.34%
CURRENT VS 5Y AVG
+116.03%
CURRENT VS 10Y AVG
+105.54%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-5.63x
median of 441 covered companies
CURRENT VS SECTOR MEDIAN
+110.66%
vs the sector median at left
AnaptysBio, Inc.
Market Cap
$1.44B
Interest Coverage Ratio
0.60x
TTM Avg
1.05x
3Y Avg
-2.69x
5Y Avg
-3.74x
Market Cap
$1.44B
Interest Coverage Ratio
-8.63x
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.41B
Interest Coverage Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.41B
Interest Coverage Ratio
-11.07x
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.42B
Interest Coverage Ratio
7.70x
TTM Avg
6.59x
3Y Avg
5.19x
5Y Avg
6.41x
Market Cap
$1.46B
Interest Coverage Ratio
30.72x
TTM Avg
19.49x
3Y Avg
15.15x
5Y Avg
21.38x
Market Cap
$1.48B
Interest Coverage Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.47B
Interest Coverage Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.48B
Interest Coverage Ratio
1.06x
TTM Avg
1.06x
3Y Avg
1.45x
5Y Avg
1.23x
| NAME | MARKET CAP | INTEREST COVERAGE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| AnaptysBio, Inc. (ANAB) | $1.44B | 0.60x | 1.05x | -2.69x | -3.74x |
| Ultragenyx Pharmaceutical Inc. (RARE)vs › | $1.44B | -8.63x | N/A | N/A | N/A |
| Kailera Therapeutics, Inc. (KLRA)vs › | $1.41B | N/A | N/A | N/A | N/A |
| Inhibrx Biosciences Inc. (INBX)vs › | $1.41B | -11.07x | N/A | N/A | N/A |
| The Pennant Group, Inc. (PNTG)vs › | $1.42B | 7.70x | 6.59x | 5.19x | 6.41x |
| Healthcare Services Group, Inc. (HCSG)vs › | $1.46B | 30.72x | 19.49x | 15.15x | 21.38x |
| Braveheart Bio, Inc. (BRVE)vs › | $1.48B | N/A | N/A | N/A | N/A |
| Maze Therapeutics, Inc. (MAZE)vs › | $1.47B | N/A | N/A | N/A | N/A |
| Certara, Inc. (CERT)vs › | $1.48B | 1.06x | 1.06x | 1.45x | 1.23x |
| GH Research PLC (GHRS)vs › | $1.50B | -131.05x | N/A | N/A | N/A |
Interest Coverage
0.6x
Debt/Equity
25.47
Current Ratio
5.61
Formula: Interest Coverage = EBIT / Interest Expense
Reference ranges:
Note: Interest coverage should be compared with historical interest expense, operating income, and industry capital structure.
Interest Coverage = EBIT / Interest Expense
The interest coverage ratio measures operating earnings relative to interest expense.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | INTEREST COVERAGE RATIO |
|---|---|
| 2026-06-30 | 3.29x |
| 2026-03-31 | -1.66x |
| 2025-12-31 | 3.39x |
| 2025-09-30 | 1.54x |
| 2025-06-30 | -1.33x |
| 2025-03-31 | -1.52x |
| 2024-12-31 | -0.56x |
| 2024-09-30 | -1.48x |
| 2024-06-30 | -3.68x |
| 2024-03-31 | -6.68x |
| 2023-12-31 | -8.50x |
| 2023-09-30 | -8.52x |
| 2023-06-30 | -9.21x |
| 2023-03-31 | -10.24x |
| 2022-12-31 | -6.11x |
| 2022-09-30 | -4.83x |
| 2022-06-30 | -4.74x |
| 2022-03-31 | -6.54x |
| 2019-12-31 | -111.29x |
| 2019-09-30 | -140.60x |
| 2019-06-30 | -95.22x |
| 2019-03-31 | -77.41x |
| 2018-12-31 | -53.87x |
| 2018-09-30 | -42.22x |
| 2018-06-30 | -33.06x |
| 2018-03-31 | -34.94x |
| 2017-12-31 | -15.68x |
| 2017-09-30 | -20.10x |
| 2017-06-30 | -5.82x |
| 2017-03-31 | -23.34x |
| 2016-12-31 | -28.59x |
| 2016-09-30 | -9.27x |
| 2016-06-30 | 20.37x |
| 2016-03-31 | -9.90x |
| 2015-12-31 | -30.97x |
| 2015-09-30 | -6.03x |
| 2015-06-30 | 5.33x |
| 2015-03-31 | 3.08x |
| 2014-12-31 | 52.60x |
| 2014-09-30 | 3473.00x |
